DarioHealth Corp. (DRIO)

Over the past six months, DarioHealth announced a 20-to-1 reverse stock split and reported Q2 2025 revenue of $5.4 million. The company secured new employer contracts and a $17.5 million private placement, initiating a strategic review. DarioHealth signed new employer clients and collaborated with OneStep for fall risk assessment technology. The company reported Q3 2025 revenue of $5.0 million and presented data on medical cost reduction. DarioHealth exceeded its 2025 new client target and launched DarioIQ™ AI integration. The company surpassed 100 scientific studies, following which the stock declined 3.05%. The stock price has declined over the past year.

The provided information does not explicitly detail demand seasonality for DarioHealth Corp.'s products and services. However, the nature of chronic condition management suggests a relatively consistent demand throughout the year.

DarioHealth Corp. is a digital health company focused on transforming chronic condition management through its user-centric, multi-chronic condition digital therapeutics platform. The company operates in the Health Technology sector, specializing in digital therapeutics and chronic disease management. DarioHealth's platform offers personalized interventions driven by data analytics and coaching, addressing metabolic conditions like diabetes, hypertension, and weight management, musculoskeletal pain, and behavioral health issues. The platform integrates connected devices with real-time data analytics and AI to provide personalized guidance. DarioHealth serves health plans, employers, care providers, and consumers globally.

DarioHealth Corp. operates in the United States, Canada, the European Union, Australia, and New Zealand. The company has offices in New York, United States, and Israel.

DarioHealth maintains a strong brand reputation, evidenced by high app ratings, a high Net Promoter Score, and extensive clinical evidence. Recent publications highlight the effectiveness of Dario's solutions, and the company's success in securing new clients and partnerships enhances its reputation.

DarioHealth Corp. has 22 institutional owners holding 685,318 shares, including Nantahala Capital Management, LLC, and Vanguard Group Inc. Key individual owners include David Weintraub, Yossi Bahagon, Oren Fuerst, and Erez Raphael. Individual insiders collectively hold 21.5% of the shares.